Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
Minister was briefed on the nationwide dengue situation
Education on Inhalation Therapy & Conducting Nationwide Awareness Camps, Alkem Breathe Initiative Addresses the Alarming Increase in Respiratory Diseases in India
‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic
Also to be launched Scheme for promotion of Research and Innovation in Pharma MedTech Sector (PRIP)
India is promoting holistic healthcare with emphasis on preventive care
The medical center at the Buddh International Circuit will be under the care of the Indraprastha Apollo Hospital team
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD)
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
Subscribe To Our Newsletter & Stay Updated
